j j agrees 25bn guidant deal pharmaceutical giant johnson johnson has agreed to buy medical technology firm guidant for 25.4bn 13bn . the move by johnson johnson has been widely expected and the firm will pay 76 for each guidant share 6 more than wednesday s closing price. a number of johnson johnson s products are facing patent expirations while the company is also battling fierce competition from generic products. analysts said that the deal is aimed at offsetting johnson johnson s reliance on a slowing drug business. meanwhile demand for defibrillators which give the heart a small electric shock when an irregular heartbeat or rhythm is detected is expected to increase analysts said.